Rapid Prototyping and Deployment of a Therapeutic Pan-Coronavirus Fusogenix DNA Vaccine Engineered to Eliminate ADE

  • Lewis, John David J. (PI)
  • Duncan, Roy (CoPI)
  • Halperin, Scott Alan S.A. (CoPI)
  • Kelvin, Alyson Ann A.A. (CoPI)

Project: Research project

Project Details

Description

In this project, this team will rapidly develop, validate and clinically evaluate a novel DNA Vaccine against COVID-19 utilizing well-validated Fusogenix proteolipid vehicle (PLV) intracellular delivery platform. The use of a plasmid DNA vaccine will allow us to utilize multiple epitopes from key immunogenic SARS-COV-2 proteins, generating protection against structural components of the novel coronavirus, which should not only protect against viral entry but provide a robust cell-based response during active infection. Working with an international multi-disciplinary team including investigators at University of Alberta, Dalhousie University, Entos Pharmaceuticals, VIDO, EpiVax, Virscio and a pharmaceutical partner, we will rapidly prototype, validate and clinically evaluate a pan-coronavirus DNA vaccine. Clinical trials will be initiated at the Canadian center for Vaccinology in Halifax within 8 weeks of project initiation, with the goal of a commercial release within one year.

StatusFinished
Effective start/end date6/1/209/30/20

Funding

  • Institute of Infection and Immunity: US$3,146,432.00

ASJC Scopus Subject Areas

  • Immunology
  • Virology
  • Infectious Diseases